Climb Bio, Inc.

CLYM Nasdaq SEC CIK 1768446
Follow Climb Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$14.6M −13.1% vs same quarter last year
EPS, diluted −$0.18 +5.3% vs same quarter last year
Operating cash flow −$12M +1.1% vs same quarter last year
Operating income −$16.9M −13.4% vs same quarter last year
Net income by quarter
−$8.4M
−$20.8M
−$8.7M
−$12.9M
−$17.5M
−$13.7M
−$13.5M
−$14.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$59.9M
FY24−$73.9M
FY23−$35.1M
FY22−$45.2M
FY21−$47.5M
FY20−$20.7M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$54.5M
FY24−$15.6M
FY23−$20.6M
FY22-
FY21-
FY20-
FY19-